Amela Biosciences Attends Swiss Nordic Bio 2026 in Zurich
Amela Biosciences attended Swiss Nordic Bio 2026, the Zurich biotech and investor conference connecting Swiss, Austrian, and Nordic biotech, medtech, and pharma companies.
Back to Home
News and Insights
Amela Biosciences Attends ILMAC Lausanne 2026
Amela Biosciences attended ILMAC Lausanne 2026, the Swiss trade fair for research and development in pharmaceuticals, chemicals, and biotechnology, held on September 22–23.
Amela Biosciences Welcomes Burak Ozan as Chief Scientific Officer
Amela Biosciences has appointed Burak Ozan as Chief Scientific Officer. Burak will lead the application of Amela's protein bioinks, from advanced cell culture and organoids to biofabrication and tissue engineering, translating user and customer requirements into bioink specifications, and will work with the founding team on scientific direction and company strategy. A bioengineer by training, he holds a PhD in Biomedical Sciences from the University of Bern with a specialization in stem cells and regenerative medicine, focused on developing personalized organoid disease models. He previously worked at BaseLaunch, the Basel-based biotech venture builder, with early-stage ventures, founders, and investors across the Swiss biotech ecosystem.
Interested in working with us?
Reach out to discuss pilot access, collaborations, or how our bioinks could support your research.
Amela Biosciences Qualifies for Final Pitch of Swiss Innovation Challenge 2026
Amela Biosciences has qualified for the final pitch of the Swiss Innovation Challenge 2026. The concluding phase invites selected finalists to refine the business plan, add an implementation concept, and prepare the final presentation for the jury. The winners and their ranking will be announced at the award ceremony on 26 November 2026. The team thanks the Swiss Innovation Challenge for the seminars, the exchange with coaches and mentors, and the chance to discuss the case. Amela Biosciences looks forward to the final pitch on 26 October 2026 and congratulates all fellow finalists.
Amela Biosciences Receives CHF 40,000 from Venture Kick for Stage 2
Amela Biosciences AG receives CHF 40,000 from Venture Kick to accelerate animal-free bioink commercialization. The company has secured funding to advance its animal-free protein bioinks for 3D cell culture. Its self-assembling materials support different tissue types while improving reproducibility and standardization, reducing reliance on animal-derived and synthetic materials. With the Stage 2 funding, the team will advance customer evaluations of its bioinks, transfer production from lab scale to a manufacturing partner, and strengthen the team, supply chain, and commercial visibility. By enabling more standardized and animal-free 3D cell culture, Amela Biosciences is helping advance reproducible biomedical research.
Amela Biosciences Selected as Venture Kick Stage 1 Winner
Amela Biosciences has been selected as a Venture Kick Stage 1 winner. Venture Kick supports Swiss startups on their path from idea to market, and the funding will contribute to Amela's market entry activities, production readiness, and team development. Amela develops protein bioinks that enable reproducible, animal-free 3D cell culture and biofabrication, advancing the transition to human-relevant research.
Amela Biosciences Featured in Vaterland on Animal-Free Bioink Technology
Amela Biosciences was featured in Vaterland, Liechtenstein's leading daily newspaper, in an article exploring how the company is advancing animal-free protein bioinks for reproducible cell-based research. The piece discusses Amela's modular platform approach, in which structural and biological signalling components can be tuned independently to match specific tissue types. The article also covers the company's vision for improving reproducibility in cell research, its potential to reduce reliance on animal-derived materials, and the longer-term outlook for tissue and organ models in drug development and rare disease research.
Amela Biosciences Presents at Startfeld Investors Day June 2026
Amela Biosciences presented at the Startfeld Investors Day June 2026, an event organized by Startfeld, the startup funding initiative of the Switzerland Innovation Park Ost, that brought together selected startups and investors around scalable business models and market-ready innovations. Alongside Adminity, MOOST, Idunox, Savely, RAIIS, Scalvio, Skaaltec, and Apolarion, Amela Biosciences shared its work on designed, animal-free protein bioinks for reproducible in-vitro biology.
Amela Biosciences Qualifies for Second Round of Swiss Innovation Challenge 2026
Amela Biosciences has qualified for the second round of the Swiss Innovation Challenge 2026. The programme, run by Wirtschaftskammer Baselland and the University of Applied Sciences and Arts Northwestern Switzerland FHNW, advances more than 100 innovation projects through three pitch rounds to select three finalists and one award winner. Participants gain access to seminars, coaching, mentoring, and networking events.
Amela Biosciences AG Registered in the Swiss Commercial Register
Amela Biosciences AG (Amela Biosciences Ltd.) has been entered in the Swiss Commercial Register, St. Gallen, with a statute date of 29 May 2026. Its purpose covers the commercialisation, research, development, manufacturing, and trade of products, technologies, and services in the life sciences and research sectors.
Amela Biosciences Named Finalist at Startfeld Diamant 2026
Amela Biosciences reached the final of the Startfeld Diamant 2026, the young entrepreneur award by St. Galler Kantonalbank recognising the most innovative and scalable start-ups in Eastern Switzerland. In the Diamant category, Catchfree won the main prize for its plant-based seafood products and Fortyfour took the Rohdiamant for its direct-air CO₂ capture technology. As a Diamant finalist alongside Ofinto, Amela Biosciences was awarded CHF 5,000 for developing designed, animal-free protein bioinks for reproducible in-vitro biology.
Amela Biosciences at Swiss Startup Days 2026 in Bern
Amela Biosciences will be at Swiss Startup Days 2026 at Kursaal, Bern, on May 21, 2026. The team is looking to exchange perspectives and discuss collaboration and funding opportunities with investors and peers, focused on advancing a protein bioink platform for cell-based models, tissue engineering, and regenerative medicine.
FDA Draft Guidance on Alternatives to Animal Testing — A Milestone for Human-Relevant Research
The FDA's draft guidance on alternatives to animal testing marks an important step toward human-relevant research, providing clearer direction on how New Approach Methodologies (NAMs) can be translated into regulatory practice. Methods are evaluated in context of use, supported by scientific validation demonstrating reliability, reproducibility, and human biological relevance. At Amela Biosciences, we are contributing to this shift by developing engineered protein bioinks for tailored cell matrices, supporting reproducible in vitro systems for human-relevant biology.
Amela Biosciences at START Summit 2026 in St. Gallen
Amela Biosciences will be at START Summit 2026 in St. Gallen. We enable a shift where biology becomes the starting point of experimental design, allowing researchers to build experimental systems around their cells and opening new capabilities in advanced in vitro models and biofabrication. Our tailored cell matrices support consistent and reproducible experiments, enable diverse cell systems, and contribute to scalable, animal-free and human-relevant research.
Amela Biosciences Selected for >>venture>> Startup Competition
Amela Biosciences is officially part of the >>venture>> Startup Competition. With 451 applications this year, the competition continues to grow and highlight the strength of the Swiss startup ecosystem. The semi-finalists across the competition verticals will be announced on April 16.
Amela Biosciences Among Top 3 Finalists — Startfeld Diamant 2026
Amela Biosciences has been selected as one of three finalists in the Diamant category of the Startfeld Diamant 2026 Young Entrepreneur Award by St. Galler Kantonalbank. The competition recognizes young companies from Eastern Switzerland with innovative and scalable business models. The two-stage selection process includes expert evaluation, management seminars, and a final pitch before the jury, with the award ceremony on June 3, 2026.
Amela Biosciences Selected Among STAGE UP Top 14
Following its elevator pitch at STAGE UP in Bern on January 27, 2026, Amela Biosciences has been selected as one of the teams advancing to the next stage.
Amela Biosciences at the European Workshop on Biotechnology: Bio-based Materials
Amela Biosciences presented its technology platform at the European Workshop on Biotechnology: Bio-based Materials, held from February 2–5, 2026 on the Energypolis Campus. Organized by the Bio-based Materials Division of the European Federation of Biotechnology (EFB) in collaboration with HES-SO Valais-Wallis and HEIA-FR, the event brought together international experts from across Europe and Canada, combining lectures, hands-on laboratory sessions, and collaborative workshops on topics ranging from biopolymers to enzymatic degradation and synthetic biology.